School-Based Treatment With ACT to Reduce Transmission

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

We propose to evaluate the community-level impact of intermittent preventive treatment (IPT) for malaria in schoolchildren on clinical outcomes and malaria transmission, using a cluster-randomised design in Jinja, Uganda. Dihydroartemisinin-piperaquine (DP) will be administered to schoolchildren monthly for up to six rounds of treatment during one school year. Outcomes will be measured using surveys of communities, schoolchildren, and mosquito vectors. Our proposal also includes health service research to evaluate the potential feasibility of taking the programme to scale, which will guide future research and implementation of the intervention, and help shape policies in Uganda and elsewhere in Africa.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Collaborators: Infectious Diseases Research Collaboration, Uganda; University of California, San Francisco; University of Durham
• Treatments: Artemisinins; Artenimol; Dihydroartemisinin; Piperaquine

Criteria

For IPT intervention

Inclusion Criteria:

1. Student enrolled in a participating intervention school.

2. Willingness of parent/guardian to provide written informed consent.

3. Provision of written assent by the student (aged 8 years or above).

Exclusion Criteria:

1. Age < 5 years

2. Known allergy or history of adverse reaction to DP

3. Menarche in female students

4. Weight < 11 kg

5. History of cardiac problems or fainting

6. Family history of long QT syndrome

7. Current use of medications known to prolong the QT interval

8. Not able to locate parent or guardian, after at least three attempts including parent/teacher association (PTA) meetings and home visits

9. Not able to locate the student at school, after at least three attempts